Drug Trial Radar · NCT06497985
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Dec 6, 2024
Primary completion
May 31, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
Conditions
- Colorectal Cancer
Interventions
TucidinostatDrug
30mg orally BIW
SintilimabDrug
200 mg intravenously (IV) Q3W
BevacizumabDrug
7.5mg/kg intravenously (IV) Q3W
FruquintinibDrug
5mg orally QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rui-Hua Xu
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.